GNLX

Conviction 15HealthcareScan · Mon, Aug 10, 2026

GNLX$2.73+2.44%

ResistanceSupportVol 14Insider sell

Vol MA14 298.73K

May 11May 28Jun 16Jul 6Jul 23Aug 10

GENELUX CorpPHARMACEUTICAL PREPARATIONSwww.genelux.com ↗

Price2.73

Change+2.44%

Gap+0.56%

Rel volume1.74×

Avg volume250.98K

Avg $ vol700.78K

SMA 202.86

SMA 502.92

SMA 2003.45

Price vs 50-6.58%

Price vs 200-21.04%

MA stackbearish

50/200 cross—

Supertrenddown · 3.19

RSI (14)45

MACD hist-0.03

MACD crossbear · 4d

Stoch %K / %D39 / 34

ADX (14)18

+DI / −DI8 / 20

RSI divergence—

MACD divergence—

ATR %+6.48%

ADR %5.70%

52w high8.24

52w low2.30

From 52w high-66.93%

Above 52w low+18.48%

New 52w highNo

SqueezeOff

Bollinger width17.39%

%B0.23

Donchian pos38.79%

Donchian high3.08

Donchian low2.50

AVWAP (52w high)3.29

vs AVWAP high-17.18%

AVWAP (52w low)2.83

vs AVWAP low-3.66%

OBV trendDown

Chaikin MF (20)-0.13

Today vs 20d1.74×

Avg vol (14d)298.73K

Avg vol (20d)250.98K

Avg $ vol (20d)700.78K

Market cap122.19M

RS 3m (vs SPY)-11.70%

RS 6m (vs SPY)-0.92%

RS line new highNo

Trend template0/8

Technical rank35.4

1 week-8.56%

1 month-10.07%

3 months-12.38%

6 months+14.02%

1 year-18.41%

YTD-40.11%

P/E-3.80

P/B5.33

P/S—

P/FCF-4.63

EPS-0.8600

Div yield—

ROE-140.24%

ROA-99.30%

Debt/Eq0.04

Current3.68

EV/EBITDA—

Gross margin—

Net margin—

Rev growth0.00%

EPS growth-7.62%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value113.82M

Revenue8K

Net income-8.93M

Gross profit—

Free cash flow-26.37M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out44.84M

Employees26

ListedThu, Jan 26, 2023

Free float38.23M

Float %85.3%

Short interest3.11M

Days to cover17.9d

Short volume75.6%

Squeeze score72 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction15 / 100

Pattern quality—

Tech rank35.4 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance3.15

Support2.50

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GNLX

All disclosures →

No recent disclosed trades by Congress in GNLX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GNLX · 10 buys

Insider	Side	Shares	Value	Traded	Filed
Smither John W Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Smither John W Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Yu Yong Chief Scientific Officer · Common Stock · 2026-06-16	Grant	119.32K	—	2026-06-16	2026-06-18
Cappello Joseph Chief Technical Officer · Common Stock · 2026-06-16	Grant	174.84K	—	2026-06-16	2026-06-18
Mirabelli Mary Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Mirabelli Mary Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Thomas John Director · Common Stock · 2026-06-16	Grant	28.41K	—	2026-06-16	2026-06-18
Tyree James L Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Thomas John Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31.57K	—	2026-06-16	2026-06-18
Zindrick Thomas President and CEO · Common Stock · 2026-06-16	Grant	730.6K	—	2026-06-16	2026-06-18

SEC filings

EDGAR filings in GNLX · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.